Streamlining electronic reporting of serious adverse events (SAEs) using the REDCap data collection system: the eSAE Project
Black J. et al, (2024), Trials
Intravenous iron to treat anaemia following critical care: a multicentre feasibility randomised trial.
Shah A. et al, (2022), Br j anaesth, 128, 272 - 282
A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial
Hinks T. et al, (2021), Thorax, 76
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.
Hinks TSC. et al, (2021), Lancet respir med, 9, 1130 - 1140
Hand Osteoarthritis: investigating Pain Effects of estrogen-containing therapy (HOPE-e): a protocol for a feasibility randomised placebo-controlled trial.
Marian IR. et al, (2021), Pilot feasibility stud, 7
Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.
Nanchahal J. et al, (2018), Ebiomedicine, 33, 282 - 288
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study.
Nanchahal J. et al, (2017), Wellcome open research
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.
Nanchahal J. et al, (2017), Wellcome open res, 2
Integration of the Cancer-Related Pro-Inflammatory Response as a Stratifying Biomarker of Survival Benefit with Sorafenib in Hepatocellular Carcinoma
Howell J. et al, (2016), Journal of hepatology, 64, S195 - S195
Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity.
Wells JW. et al, (2007), Cancer immunol immunother, 56, 1861 - 1873
An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.
Chan L. et al, (2006), Cancer immunol immunother, 55, 1017 - 1024
Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells.
Chan L. et al, (2005), J virol, 79, 13190 - 13194
709 Comparison of monocyte versus CD34+ precursors for the generation of clinical grade dendritic cells for immunotherapy protocols in hepatocellular carcinoma
(2005), Journal of hepatology, 42, 258 - 259
Influence of interleukin-4 on the phenotype and function of bone marrow-derived murine dendritic cells generated under serum-free conditions.
Wells JW. et al, (2005), Scand j immunol, 61, 251 - 259
IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.
Chan L. et al, (2005), Mol ther, 11, 120 - 131
Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J. et al, (2004), Cancer immunol immunother, 53, 963 - 977